Radium ra-223
Radium ra-223 is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| A9606 | Radium ra-223 dichloride, therapeutic, per microcurie |
Clinical
Clinical Trials
18 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Rabies | D011818 | A82 | 2 | 4 | 5 | — | 4 | 13 | |
| Communicable diseases | D003141 | 1 | 1 | 1 | — | — | 2 | ||
| Virus diseases | D014777 | B34 | — | — | 1 | — | — | 1 | |
| Rna virus infections | D012327 | — | — | 1 | — | — | 1 | ||
| Rhabdoviridae infections | D018353 | EFO_0007469 | — | — | 1 | — | — | 1 | |
| Mononegavirales infections | D018701 | EFO_0007376 | — | — | 1 | — | — | 1 | |
| Healthy volunteers/patients | — | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Zoonoses | D015047 | 1 | 1 | — | — | — | 1 | ||
| Rabies virus | D011820 | NCBITaxon_11292 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | RADIUM RA-223 |
| INN | — |
| Description | Radium-223 (223Ra, Ra-223) is an isotope of radium with an 11.4-day half-life. It was discovered in 1905 by T. Godlewski, a Polish chemist from Kraków, and was historically known as actinium X (AcX). Radium-223 dichloride is an alpha particle-emitting radiotherapy drug that mimics calcium and forms complexes with hydroxyapatite at areas of increased bone turnover. The principal use of radium-223, as a radiopharmaceutical to treat metastatic cancers in bone, takes advantage of its chemical similarity to calcium, and the short range of the alpha radiation it emits.
|
| Classification | Small molecule |
| Drug class | quaternary ammonium derivatives |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | [223Ra] |
Identifiers
| PDB | — |
| CAS-ID | 15623-45-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297420 |
| ChEBI ID | — |
| PubChem CID | 6335825 |
| DrugBank | DB12813 |
| UNII ID | — |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
27 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more